Latest Breaking News On - பரப்பளவு கீழ் - Page 5 : comparemela.com
Barrikaden angezündet: Krawalle nach Aufstieg von Hansa Rostock
ligaportal.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ligaportal.at Daily Mail and Mail on Sunday newspapers.
«Артистка будет наказана»: Ани Лорак лишилась бизнеса после скандала с Меладзе
lratvakan.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lratvakan.com Daily Mail and Mail on Sunday newspapers.
В Сальвадоре возле дома экс-копа нашли зарытые тела 8 человек: вероятно женщин (фото)
unian.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unian.net Daily Mail and Mail on Sunday newspapers.
Lexaria Bioscience Corp.: Lexaria s Newest DehydraTECH 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
Human clinical hypertension study HYPER-H21-1 also progressing
KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the Company or Lexaria ), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new DehydraTECH 2.0 cannabidiol ( CBD ) formulations in its second 2021 applied research and development study program, HYPER-A21-2. One of our latest DehydraTECH 2.0 formulations gave us the strongest absorption enhancement results we ve ever recorded, at 2,708% more CBD into bloodstream during the study period than the representative industry standard MCT control formulation. It was also 174% more effective than the original DehydraTECH 2.0 formulation from 2019, said Chris Bunka, CEO of Lexaria. This is a 27-fold improvement
Lexaria s Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
ACCESSWIRE
New formulation delivers up to 2,708% more CBD into bloodstream
Human clinical hypertension study HYPER-H21-1 also progressing
KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (CSE:LXX) (the Company or Lexaria ), a global innovator in drug delivery platforms, is pleased to announce successful test results of two new DehydraTECH
™ 2.0 cannabidiol ( CBD ) formulations in its second 2021 applied research and development study program, HYPER-A21-2. One of our latest DehydraTECH 2.0 formulations gave us the strongest absorption enhancement results we ve ever recorded, at 2,708% more CBD into bloodstream during the study period than the representative industry standard MCT control formulation. It was also 174% more effective than the original DehydraTECH 2.0 formulation from 2019, said